Current Guidance* Previous Guidance Guidance $ Reported % Increase (Decrease) Constant Currency % Increase (Decrease) Organic excluding COVID-19 % Increase Guidance $ Fiscal 2024 Revenue $4,000 - $4,050 (0.8%) to 0.5% (0.8%) to 0.4% 5.1% to 6.5% $3,990-$4,065 GAAP EPS $3.45 - $3.55 88.5% to 94.0% $3.52-$3.67 Non-GAAP EPS $4.02 - $4.12 1.5% to 4.0% $3.97-$4.12 Q3 2024 Revenue $992.5 - $1,007.5 0.8% to 2.4% 1.2% to 2.7% 4.0% to 5.6% GAAP EPS $0.80 - $0.87 600.0% to 643.8% Non-GAAP EPS $0.98 - $1.05 5.4% to 12.9% *Fiscal 2024 has four fewer selling days compared to fiscal 2023. Factored into our guidance, we estimate the impact of the four fewer selling days to be a headwind of more than 100 bps for the full year. Previously provided fiscal year revenue guidance midpoint of $4,027.5 million ($4,015.5 million in constant currency), compared to current revenue guidance midpoint of $4,025 million ($4,022 million in constant currency). Use of Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; organic revenues excluding COVID-19, non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; adjusted EBITDA; adjusted net leverage ratio and adjusted ROIC. Organic revenue for the fiscal second quarter of 2024 excludes the divested Blood Screening and SSI ultrasound imaging businesses. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition. Organic revenue excluding COVID-19 revenues is organic revenue less COVID-19 assay revenue, COVID-19 related sales of instruments, collection kits and ancillaries, COVID-19 related revenue from Diagenode and Mobidiag, as well as COVID-19 related license reve

later in the release …

the item shown at left

other guidance in this release

Text is the filed exhibit, verbatim.